×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | Health Topics | Vaccines | COVID | Pfizer | vaccine | effective

Pfizer's COVID-19 Vaccine Trial Shows Long-term Efficacy in Adolescents

Pfizer vial with COVID-19 vaccine and a syringe in the vial
(Dreamstime)

Monday, 22 November 2021 07:22 AM

Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

© 2022 Thomson/Reuters. All rights reserved.


Health-News
Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over...
COVID, Pfizer, vaccine, effective, long-term, adolescents
140
2021-22-22
Monday, 22 November 2021 07:22 AM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved